Transmission of drug resistance from treatment-experienced patients to newly infected persons has been observed repeatedly in countries with access to antiretroviral therapy [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] . Reports in the literature suggest that 8%-30% of people who contract HIV infection in Europe or the United States acquire a virus with drug resistance-conferring mutations [12] [13] [14] (reviewed in [15] ). The transmission of drug-resistant strains increases despite all prevention efforts, raising major public health concerns [16] . The clinical management of patients who have never been exposed to therapy may be unfavorably affected [17] [18] [19] [20] .
Although the incidence of HIV infection in Israel is relatively low (47 cases per million persons in 2000) [21] , the prevalence is much higher among particular groups. Most of the infected patients or their parents contracted the virus in other countries. Infected immigrants had come from many parts of the world. Consequently, most of the circulating subtypes and recombinants can be found in various proportions. The major groups are the following: Israeli citizens of Ethiopian origin, who account for only 1.7% of the total population [22] but contribute 45.4% of all new HIV/AIDS cases diagnosed [21] ; injection drug users who recently immigrated from the former Soviet Union, where a large epidemic among injection drug users broke out in the late 1990s [23] ; and men who have sex with men, usually infected in Israel or in other Western countries. These 3 groups can be clearly distinguished demographically, by risk behavior category and by virus subtype. Cross-infection between groups is very rare. The general availability of antiretroviral treatment in Israel leads to transmission of resistant virus among members of each group. We investigated the frequency of drug-resistant HIV infection among drug-naive patients within the different groups.
METHODS
Clinical specimens and database. Samples obtained from drug-naive patients selected at random by the treating physicians between June 1999 and June 2003 were sent for genotypic analysis to the National HIV Reference Laboratory (NHRL; TelHashomer, Israel). Participating physicians from the different national AIDS health care centers sent all patients who arrived for follow-up visits during the relevant period without further selection. The treatment center laboratories determined plasma HIV RNA levels and CD4 + T cell counts. Demographic information (including date and place of birth, date of immigration to Israel, and presumed locale where infection was acquired), together with the current CD4 + cell counts and HIV RNA levels, were provided by the participating physicians on standardized forms along with the samples and were stored in an anonymous database at the NHRL. Subtype identification was based on comparing the polymerase sequence with consensus sequences from the Stanford public database (http://hivdb.stanford.edu) [24] [25] [26] . Several sequences documented in the present study are shared with SPREAD, a scientific surveillance program supported by the European Commission [27] (authors' unpublished data).
HIV-1 RNA extraction and sequencing. Extraction and genotyping of viral RNA were performed as described elsewhere [28] .
Statistical analysis. Clinical data and individual mutation frequencies were compared across patient groups by the x 2 test and Fisher's 2-tailed exact test. A mutation summary score was computed for each of the 3 groups of drugs by adding the number of mutations present. The mutation summary scores were compared across patient groups with the Wilcoxon rank sum test.
Phylogenetic analysis. Phylogenetic relationships of newly derived viral sequences were estimated from comparisons with previously reported representative HIV-1 isolates. These are listed in figure 1. The comparison was made by use of the CLUSTAL W profile alignment option. The sequences were aligned according to their nucleotides (nucleotides 2262-2549 and 2659-3290 of HXB2 [GenBank accession number K03455] of the protease amino acids 4-99 and reverse transcriptase amino acids 38-248, respectively). A tree was drawn by the TreeView program.
RESULTS

Screening of HIV-infected patients.
HIV/AIDS case management is done in 7 regional AIDS centers in Israel. Testing for HIV by ELISA is available on request, free of charge. In addition, all new immigrants from Ethiopia aged 19 years are screened for HIV infection on arrival. Systematic screening is done in jails and for some military recruits [21] . Regional laboratories and the blood services perform ELISA testing for HIV antibodies. All samples positive by ELISA are forwarded to the NHRL for confirmation by Western blot analysis. Confirmed cases are reported back to the medical source of specimen and to the AIDS Department in the Ministry of Health, where the data are stored in a National Register. About 300 new patients were given a diagnosis of HIV infection each year during the study period.
Because no systematic screening for resistance is done in Israel, samples from patients with new diagnoses were collected at random by participating physicians at the HIV treatment centers and sent to the NHRL. Plasma samples were collected from patients coming for a second consultation, together with plasma used to determine baseline CD4 + cell counts and viral RNA. All samples received at NHRL by July 2003 were genotyped and were included in the study. The participating physicians sent all patients who arrived for follow-up during the relevant period without further selection. These constituted between 12% (large centers) and 60% (small centers) of all patients who were given diagnoses at the participating health care centers (5 of 7) during the study period. The donors made up 115% of all patients with new diagnoses between June 1999 and June 2003. Distribution of risk groups in the collected samples was in accordance with the prevalence of these groups in the population of infected patients during these years (58%, 24%, and 10% heterosexuals, injection drug users, and men who have sex with men, respectively, in the study samples, and 62%, 25%, and 13% in the total population; ); 51% of P p 1 the study patients were of Ethiopian origin, compared with 50% in the total population ( ). P p 1 Patients and sample classification. Sequences were obtained from a total of 178 drug-naive patients. These included 42 with A subtypes (20 with subtype A, 20 with AE, and 2 with AC), 29 with subtype B, 100 with subtype C, and 5 with subtype F (table 1) . Samples from 2 patients did not amplify and were excluded from this study.
Most of the patients had recently been given a diagnosis of HIV infection (median, 3 days since confirmation by positive result of a Western blot assay). All 5 patients with subtype F were born and infected in Argentina. Most of the patients with A subtypes (79%) came from the former Soviet Union-in . The multiple infections involving families of epidemiologically linked viruses is depicted in the cluster of injection drug users who immigrated from the former Soviet Union infected with HIV subtype A and CRF01_AE (A); a chain of transmissions originating from a common source is evident in B: patients 333, 386, 400, 427, and 487. The latter patients received their diagnoses at 4 different centers during the last year of the study, 2 of them were diagnosed before seroconversion; no independent information regarding a common source or any other connection between these patients exists. particular, the Ukraine; 43% of patients with A subtypes are known to have been infected in the former Soviet Union, for 43% the country of infection was not available, and 14% were infected in Israel. Most patients with subtype B were born and infected in Israel (59% and 55%, respectively) and in the former Soviet Union (34% and 21%, respectively). For 14% of patients with subtype B, the country of infection was not known, and the rest (10%) were infected in various Western countries. Most patients with subtype C, or their parents, were born in Ethiopia (92%), and a few were born in the former Soviet Union (3%), Israel (2%), India, and Africa; 51% of patients with subtype C were infected in Ethiopia, and 30% were infected in Israel; for 19%, the locale where infection was acquired was unknown.
Demographic data varied between the 3 groups in a number of additional parameters: sex, age, and mode of infection (table  1) . HIV loads and CD4
+ cell counts at diagnosis were similar for the 3 groups, and although the average HIV load was lower and CD4 + cell count higher among patients with A subtypes, the differences did not reach statistical significance (table 1) .
Resistance-associated mutations and polymorphisms. Twelve patients-1 with an A subtype (2% of all with A subtypes), 3 with subtype B (10% of all with B), and 9 with subtype C (9% of all with C), or 7% of the total-had major (primary) mutations, which included the protease N88D (2 patients with subtype C) and L90M (1 with subtype C) or different combinations of reverse-transcriptase mutations, including M41L (1 with subtype B), K103N/T (1 with an A subtype, 1 with subtype B, 2 with subtype C), V106M (1 with subtype C), M184V (1 with subtype B), G190A (1 with subtype C), L210W (1 with subtype B), T215Y/F (1 each with subtype B and subtype C) or K219R (1 with subtype B). In addition, 14 patients, 1 with an A subtype (2%), 2 with subtype B (7%), and 11 with (table 3) . Resistance in drug-naive patients infected in Israel. The frequency of resistance mutations varied between patients who were infected in Israel and those infected in countries where treatment is not generally available.
Because immigrants from Ethiopia are screened for HIV infection on arrival, the locale where they were infected is well documented. Place of infection is not as completely documented for the others. Fifty-six patients are known to have been infected in Israel (7 with HIV A subtypes, 17 with subtype B, and 32 with subtype C), and 74 are known to have been infected outside of Israel; for 46, information is not available. Patients with subtype C infected in Israel received the diagnosis on average 10.7 years (median, 11 years) after their arrival, 9 of them during the acute stage of infection. Genotyping was done either immediately after diagnosis or within 13 months of their positive result of Western blot testing (median, 1.3 months). The mean HIV RNA level (‫ע‬SEM) was 904,182 ‫ע‬ copies/mL (median, 197,500 copies/mL; range, 3980-710,791 18,000,000 copies/mL), and the mean CD4 + cell count (‫ע‬SEM) was cells/mL (median, 280 cells/mL). The mean time 480 ‫ע‬ 226 after immigration to Israel that patients with subtype C had HIV infection diagnosed 0.7 years (median, 0.5 years); their mean HIV RNA level (‫ע‬SEM) was copies/ 318,189 ‫ע‬ 84,439 mL (median, 197,500 copies/mL), and the mean CD4 + cell count (‫ע‬SEM) was cells/mL (median, 251 cells/mL). 411 ‫ע‬ 97 No significant differences in HIV RNA levels and CD4 + cell counts were found between the patients with subtype C infected in Israel and those infected in the country of origin (mainly Ethiopia).
During the study period (June 1999 to June 2003), an increase in the spread of resistance was not observed. In the 4 study years, 10, 3, 7, and 6 patients, respectively, had viruses with resistance-conferring mutations. Overall, the differences were not significant.
Frequencies of resistance-conferring mutations correlated with the place where infection was acquired: higher frequencies were seen in patients infected in Israel, particularly in patients with subtype C, who acquired nonnucleoside reverse-transcriptase inhibitor-associated mutations. Among those who contracted HIV in Israel, 10 (17.9%) of 56 (1 of 7 with A subtypes, 3 of 17 with subtype B, and 6 of 32 with subtype C; P p ) carried virus with major resistance mutations, a signif-0.7-1 icantly higher proportion ( ) than the proportion in-P ! .001 fected in other countries (3 [2.5%] of 120). Six patients infected in Israel (10.7%) carried strong minor mutations, compared with 7 (5.8%) of 120 infected elsewhere or with an unknown place of acquisition of infection (table 3) .
Phylogenetic analyses of the patients' sequences was done in comparison with 7 reference strains from HIV-1 group M from the Los Alamos sequences database [33] by use of the CLUSTAL W [34] profile alignment option. As seen in figure 1, 2 kinds of transmission chains are apparent: multiple infections involving families of epidemiologically linked viruses (e.g., the cluster of injection drug users emigrating from the former Soviet Union infected with HIV subtype A and CRF01_AE; figure  1A) ; and a chain of transmissions originating from a common source (e.g., subtype C patients no. 333, 386, 400, 427, and 487; figure 1B) . The latter patients were given diagnoses at 4 different health care centers during the last year of the study, 2 of them before seroconversion; no independent information regarding a common source or any other connection between these patients exists.
DISCUSSION
We did not find significant differences in transmission of resistant virus between the groups infected with subtype B and subtype C. The rate of transmission of resistant virus within a group reflects the proportion of HIV carriers under antiretroviral treatment, the proportion of treated patients engaged in risky behavior, and factors such as adherence to treatment. Differences among the 3 groups could have been expected, reflecting differences in behavior and adherence to treatment associated with the diverse demographic characteristics and cultural backgrounds of these patients, but these factors act in a complex manner. For example, depending on the degree of nonadherence to treatment, these patients may or may not carry more resistant viruses than do adherent patients. Therefore, the similarity in transmission of resistance between groups may result from mutual cancellation of opposite effects. Alternatively, it may indicate that cultural and socioeconomic differences may be less confounding than presently thought when analyzing heterogeneous populations. A conclusive interpretation should await a more extensive investigation.
Our estimates of resistance in drug-naive patients in Israel are conservative, incorporating only major and strong minor resistance-conferring mutations. In the Stanford database [24] , these mutations are found among drug-naive patients in frequencies of 0 to 0.6% only. Three of the 4 patients with subtype C harboring M46I as the only strong minor resistance mutation were infected abroad, suggesting that this mutation in patients with subtype C might have arisen without drug selection pressure [28] . However, in the Stanford database, the frequency of this mutation in drug-naive patients is !0.2% for patients with either subtype B or subtype C.
We found drug-resistant virus in 26 (14.8%) of 176 recently infected patients. Of those who did not carry resistance-conferring mutations, at least 55% were infected in countries where drug treatment was not available (Ethiopia and the former Soviet Union). Of the 56 patients known to have been infected in Israel, 16 (28.6%) had virus harboring resistance-conferring mutations (major for 10 patients and strong minor for 6; table 3). This is 2.6-fold higher ( ) than the frequency (11.1%) P ! .001 recently reported in Europe (the CATCH Study) [27, 35] . To what extent the difference is the result of more complete treatment coverage in Israel, a higher rate of risky behavior, and/ or partial adherence remains to be determined.
Our finding of drug-resistant viruses in a significant proportion of newly infected patients implies that many HIV-infected persons receiving HAART continue to engage in riskrelated behavior. The public health implications of this include the need to intensify programs directed at such patients that address prevention of transmission.
Our results regarding the spread of drug-resistant virus in Israel support the rationale behind the guidelines recommendation for testing of all recently infected patients for drug resistance [20] . Indeed, testing for genotypic resistance before initiation of therapy has been found in a US study to be costeffective when the rate of primary resistance exceeds 4% [36] . Our data show considerable baseline drug resistance in patients with newly diagnosed HIV infection who were infected in Israel. Pretreatment resistance testing should thus be the standard of care for all persons who were recently infected either in Israel or in other countries where HAART is available to the general public. The primary purposes of such early resistance testing
